Reduced folate carrier: Biochemistry and molecular biology of the normal and methotrexate-resistant cell

British Journal of Biomedical Science

Volumn 60, Issue 2, 2003, Pages 117-129

  Bosson, Geoffrey ^a  

^a NORTHUMBRIA UNIVERSITY   (United Kingdom)

Author keywords

Drug resistance; Folic acid; Methotrexate; Molecular biology

Indexed keywords

FOLIC ACID; FOLIC ACID ANTAGONIST; METHOTREXATE; REDUCED FOLATE CARRIER;

ANIMAL CELL; ARTICLE; CELL TRANSPORT; DNA POLYMORPHISM; ENZYME INHIBITION; FOLATE METABOLISM; GENE EXPRESSION; GENE MUTATION; GENETIC CODE; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE METABOLISM; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE;

ANIMALIA;

EID: 0038779673     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: 10.1080/09674845.2003.11783687     Document Type: Article

References (76)

1. Chango A, Emery-Fillon N, Potier de Courcy G et al. A polymoprhism (80G-A) in the reduced folate carrier gene and its association with folate status and homocysteinema. Mol Genet Metab 2000; 70: 310-5.
2. Salooja N, Catto A, Carter A, Tudnesham EGD, Grant PJ. Methylene tetrahydrofolate reductase C677T genotype and stroke. Clin Lab Haematol 1998; 20: 357-61.
3. Voet D, Voet J, Pratt CW. Fundamentals of biochemistry New York: John Wiley & Sons, 1999: 631-2, 693-721.
4. Wang Y, Zhao R, Russell RG, Goldman D. Localization of the murine reduced folate carrier as assessed by immunohistochemical analysis. Biochim Biophys Acta 2000; 1513: 49-54.
5. Zeng H, Liu G, Rea PA, Kruh GD. Transport of amphipathic anions by human multidrug resistance protein 3. Cancer Res 2000; 60: 4779-84.
6. Drori S, Sprecher H, Shemer G, Jansen G, Goldman ID, Assaraf YG. Characterization of a human alternatively spliced truncated reduced folate carrier increasing folate accumulation in parental leukemia cells. Eur J Biochem 2000; 267: 690-702.
7. Trippett T, Schlemmer S, Elisseyeff Y et al. Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia. Blood 1992; 80: 1158-62.
8. Trippett TM, Bertino JR. Therapuetic strategies targeting proteins that regulate folate and reduced folate transport. J Chemother 1999; 11: 3-10.
9. Brigle KE, Spinella MJ, Westin EH, Goldman ID. Increased expression and characterization of two distinct folate binding proteins in murine erythroleukemia cells. Biochem Pharmacol 1994; 47: 337-45.
10. Wang X, Shen F, Freisheim JH, Gentry LE, Ratnam M. Differential stereospecificities and affinities of folate receptor isoforms for folate compounds and antifolates. Biochem Pharmacol 1992; 44: 1898-1901.
11. McKusick VA. Solute carrier family 19, member 1: SLC19A1. Medelian inheritance in Man. Johns Hopkins University. 〈http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=600424〉
12. Westerhof GR, Jansen G, van Emmerik N et al. Membrane transport of natural folates and antifolate compounds in murine L1210 leukemia cells: role of carrier- and receptor-mediated transport systems. Cancer Res 1991; 51: 5507-13.
13. Dixon KH, Mulligan T, Chung K-N, Elwood PC, Cowan KH. Effects of folate receptor expression following stable transfection into wild type and methotrexate transport-deficient ZR-75-1 human breast cancer cells J Biol Chem 1992; 267: 24140-7.
14. Sierra EE, Goldman ID. Recent advances in the understanding of the mechanism of membrane transport of folates and antifolates. Semin Oncol 1999; 26 (Suppl 6): 11-23.
15. Rajgopal A, Sierra EE, Zhao R, Goldman ID. Expression of the reduced folate carrier SLC19A1 in IEC-6 cells result in two distinct transport activities. Am J Physiol Cell Physiol 2001; 281: C1579-C1586.
16. Trippett TM, Garcia S, Manova K et al. Localization of a human reduced folate carrier protein in the mitochondrial as well as the cell membrane of leukemia cells. Cancer Res 2001; 61: 1941-7.
17. Horton HR, Moran LA, Ochs RS, Rawn JD, Scrimgeour KG. Principles of biochemistry (3rd Ed). Englewood Cliffs, NJ: Neil Patterson Publishers (Prentice-Hall), 1993: 582.
18. Zhang L, Wong SC, Matherly LH. Transcript heterogeneity of the human reduced folate carrier results from the use of multiple promoters and variable splicing of alternative upstream exons. Biochem J 1998; 332: 773-80.
19. Williams FMR, Flintoff WF. Isolation of a human cDNA that complements a mutant hamster cell defective in methotrexate uptake. J Biol Chem 1995; 270: 2987-92.
20. Zhao R, Sharina IG, Goldmann ID. Pattern of mutations that results in loss of reduced folate carrier function under antifolate selective pressure augmented by chemical mutagenesis. Mol Pharmacol 1999; 56: 68-76.
21. Moscow JA, Gong M, He R et al. Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells. Cancer Res 1995; 55: 3790-4.
22. Dixon KH, Lampher BC, Chiu J, Kelly K, Cowan KH. A novel cDNA restores reduced folate carrier activity and methotrexate sensitivity to transport deficient cells. J Biol Chem 1994; 269: 17-20.
23. Liu XY, Matherly LH. Functional interaction between arginine-133 and aspartate-88 in the human reduced folate carrier: evidence for a charge-pair association. Biochem J 2001; 358: 511-6.
24. Matherly LH. Molecular and cellular biology of the human reduced folate carrier. Prog Nucleic Acid Res Mol Biol 2001; 67: 131-62.
25. Wong SC, Proefke SA, Bhushan A, Matherly LH. Isolation of human cDNAs that restore methotrexate sensitivity and reduced folate carrier activity in methotrexate transport-defective chinese hamster ovary cells. J Biol Chem 1995; 270: 17468-75.
26. Ferguson PL, Flintoff WF. Topological and functional analysis of the human reduced folate carrier by hemagglutinin epitope insertion. J Biol Chem 1999; 274: 16269-78.
27. Sadlish H, Williams FM, Flintoff WF. Cytoplasmic domains of the reduced folate carrier are essential for trafficking, but not function. Biochem J 2002; 364: 777-86.
28. Liu XY, Witt TL, Matherly LH. Restoration of high-level transport activity by human reduced folate carrier/ThTr1 chimeric transporters: role of the transmembrane domain 6/7 linker region in reduced folate carrier protein. Biochem J (ePublished: BJ20020419).
29. Matherly LH, Angeles SH. Role of N-glycosylation in the structure and fucntion of the methotrexate membrane transporter from CCRF-CEM human lymphoblastic cells. Biochem Pharmacol 1994; 47: 1094-8.
30. Wong SC, Zhang L, Proefke SA, Matherly LH. Effects of the loss of capacity for N-glycoslylation on the transport activity and cellular localization of the human reduced folate carrier. Biochim Biophys Acta 1998; 1375: 6-12.
31. Nehls S, Snapp EL,Cole NB et al. Dynamics and retention of misfolded proteins in native ER membranes. Nat Cell Biol 2000; 2: 288-95.
32. Lapenta V, Sossi V, Gosset P et al. Construction of a 2.5-Mb integrated physical and gene map of distal 21q22.3. Genomics 1998; 49: 1-13.
33. Tolner B, Roy K, Sirotnak FM. Structural analysis of the human RFC-1 gene encoding a folate transporter reveals multiple promoters and alternatively spliced transcripts with 5′ end heterogeneity. Gene 1998; 211: 331-41.
34. Williams FMR, Murray RC, Underhill M, Flintoff WF. Isolation of a hamster cDNA clone coding for a function involved in methotrexate uptake. J Biol Chem 1994; 269: 5810-6.
35. Gong M, Cowan KH, Gudas J, Moscow JA. Isolation and characterization of genomic sequence involved in the regulation of the human reduced folate carrier gene (RFC1). Gene 1999; 233: 21-31.
36. Whetstine JR, Flatley RM, Matherly LH. The human reduced folate carrier gene is ubiquitously and differentially expressed in normal human tissues: identification of seven non-coding exons and characterization of a novel promoter. Biochem J 2002; 367: 629-40.
37. Tolner B, Roy K, Sirotnak F M. Organization, structure and alternate splicing of the murine RFC-1 gene encoding a folate transporter. Gene 1997; 189: 1-7.
38. Jansen G, Westerhoff GR, Jarmuszewski MJA, Kathmann I, Rijksen G, Schornagel JH. Methotrexate transport in variant human CCRF-CEM leukemia cells with elevated levels of the reduced folate carrier. J Biol Chem 1990; 265: 18272-7.
39. Whetstine JR, Matherly LH. The basal promoters for the human reduced folate carrier gene are regulated by a GC-box and a cAMP-response element/AP-1-like element. J Biol Chem 2001; 276: 6350-8.
40. Whetstine JR, Witt TL, Matherly LH. The human reduced folate carrier gene is regulated by the AP2 and Sp1 transcription factor families and a functional 61 base pair polymorphism. J Biol Chem 2002 (ePublished: M208296200).
41. Ding BC, Whetstine JR, Witts TLM Schuetz JD, Matherly LH. Repression of human reduced folate carrier gene expression by wild-type p53. J Biol Chem 2001; 276: 8713-9.
42. Lohrum MAE, Vousden KH. Regulation and function of the p53-related proteins: same family different rules. Trends Cell Biol 2000; 10: 197-202.
43. Zhang L, Wong SC, Matherly LH. Structure and organization of the human reduced folate carrier gene. Biochem Biophys Acta 1998; 1442: 389-93.
44. Brigle KE, Spinella MJ, Sierra EE, Goldman ID. Organization of the murine reduced folate carrier gene and identification of variant splice forms. Biochem Biophys Acta 1997; 1353: 191-8.
45. Jansen G, Mauritz R, Drori S et al. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J Biol Chem 1998; 273: 30189-98.
46. Hanson CA. Haematology. In: McLactchey KD, ed. Clinical laboratory medicine. London: Williams and Wilkins, 1994: 817-63, 939-69.
47. Rots MG, Pieters R, Kaspers GJL, Veerman AJP, Peters GJ, Jansen G. Classification of ex vivo methotrexate resistance in acute lymphoblastic and myeloid leukaemia. Br J Haematol 2000; 110: 791-800.
48. Rots MG, Pieters R, Peters GJ et al. Methotrexate resistance in relapsed childhood acute lymphoblastic leukaemia. Br J Haematol 2000; 109: 629-34.
49. Mauer AM. Acute lymphocytic leukemia. In: Beutler E, Lichtman M A, Coller BS, Kipps TJ, eds. William's hematology (5th Ed). New York: McGraw Hill, 1995: Chapter 105.
50. Pui C-H, Evans WE. Acute lymphoblastic leukaemia. N Engl J Med 1998; 339: 605-15.
51. Belur LR, Boelk-Galvan D, Diers MD, McIvor RS, Zimmerman CL. Methotrexate accumulates to similar levels in animals transplanted with normal versus drug-resistant transgenic marrow. Cancer Res 2001; 61: 1522-6.
52. Warren RD, Nichols AP, Bender RA. Membrane transport of methotrexate in human lymphoblastoid cells. Cancer Res 1978; 38: 668-71.
53. Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA. The pharmacology and clinical use of methotrexate. N Engl J Med 1983; 309: 1094-104.
54. Blakley R L, Sorrentino B P. In vitro mutations in dihydrofolate reductase that confers resistance to methotrexate: Potential for clinical application. Hum Mutat 1998; 11: 259-63.
55. Hoffbrand AV, Tripp E, Catovsky D, Das KC. Transport of methotrexate into normal haemopoietic cells and into leukaemic cells and its effects on DNA synthesis. Br J Haematol 1973; 25: 497-511.
56. Masson E, Relling MV, Synold TW et al. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo, a rationale for high-dose methotrexate. J Clin Invest 1996; 97: 73-80.
57. Sadlish H, Murray RC, Williams MR, Flintoff WF. Mutations in the reduced-folate carrier affect protein localization and stability. Biochem J 2000; 346: 509-18.
58. Gong M, Yess J, Connolly T et al. Molecular mechanism of antifolate transporter-deficiency in a methotrexate-resistant MOLT-3 human leukemia cell line. Blood 1997; 89: 2494-9.
59. Ohnuma T, Lo RJ, Scanlon KJ et al. Evolution of methotrexate resistance of human acute lymphoblastic leukemia cell in vitro. Cancer Res 1985; 45: 1815-22.
60. Peters GJ, Jansen G. Folate homeostasis and antiproliferative activity of folates and antifolates. Nutrition 2001; 17: 737-8.
61. Zhang L, Taub JW, Williamson M et al. Reduced folate carrier gene expression in childhood acute lymphoblastic leukemia: relationship to immunophenotype and ploidy. Clin Cancer Res 1998; 4: 2169-77.
62. Ding BC, Witt TL, Hukku B, Heng H, Zang L, Matherly LH. Association of deletions and translocations of the reduced folate carrier gene with profound loss of gene expression in methotrexate-resistant K562 human erythroleukemia. Biochem Pharmacol 2001; 61: 665-75.
63. Gorlick R, Goker E, Trippett T et al. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood 1997; 89: 1013-8.
64. Rothem L, Ifergan I, Kaufman Y, Priest DG, Jansen G, Assaraf YG. Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukaemia cell lines. Biochem J 2002; 367: 741-50.
65. Wong SC, Zhang L, Witt TK, Proefke SA, Bhushan A, Matherly LH. Impaired membrane transport in methotrexate-resistant CCRF-CEM cells involves early translation termination and increased turnover of a mutant reduced folate carrier. J Biol Chem 1999; 274: 10388-94.
66. Zhao R, Assaraf YG, Goldmann ID. A mutated murine reduced folate carrier (RFC1) with increased affinity for folic acid, decreased affinity for methotrexate, and an obligatory anion requirement for transport function. J Biol Chem 1998; 273: 19065-71.
67. Sadlish H, Williams FMR, Flintoff WF. Functional role of arginine 373 in substrate translocation by the reduce folate carrier. J Biol Chem 2002; 277: 42105-12.
68. Zhao R, Assaraf YG, Goldmann ID. A reduced folate carrier mutation produces substrate-dependent alterations in carrier mobility in murine leukemia cells and methotrexate resistance with conservation of growth in 5-formyltetrahydrofolate. J Biol Chem 1998; 273: 7873-9.
69. Sharina IG, Zhao R, Wang Y, Babani S, Goldman ID. Mutational analysis of the functional role of conserved arginine and lysine residues in transmembrane domains of the murine reduced folate carrier. Mol Pharmacol 2001; 59: 1022-8.
70. Zhao R, Gao F, Wang PJ, Goldmann ID. Role of the amino acid 45 residue in reduced folate carrier function and ion-dependent transport as characterized by site-directed mutagenesis. Mol Pharmacol 2000; 57: 317-23.
71. Tse A, Brigle K, Taylor SM, Moran RG. Mutations in the reduced folate carrier gene which confer dominant resistance to 5,10-dideazatetrahydrofolate. J Biol Chem 1998; 273: 25953-60.
72. Roy K, Tolner B, Chiao JH, Sirotnak FM. A single amino acid difference within the folate transporter encoded by the murine RFC-1 gene selectively alters its interaction with folate analogues. J Biol Chem 1998; 273: 2526-31.
73. Zhao R, Gao F, Goldmann ID. Descrimination among reduced folates and methotrexate as transport substrate by a phenylalanine substitution for serine within the predicted eighth transmembrane domain of the reduced folate carrier. Biochem Pharmacol 1999; 58: 1615-24.
74. 27 carriers. Clin Cancer Res 2001; 7: 3416-22.
75. Rots MG, Willey JC, Jansen G et al. mRNA expression levels of methotrexate resistance-related proteins in childhood leukemia as determined by a standardized template-based RT-PCR method. Leukemia 2000; 14: 2166-75.
76. Liu S, Song L, Bevins R, Birhiray O, Moscow JA. The murine-reduced folate carrier gene can act as a selectable marker and suicide gene in hematopoietic cells in vivo. Hum Gene Ther 2002; 13: 1777-82.